Literature DB >> 21108623

Exercise alleviates Parkinsonism: clinical and laboratory evidence.

T Archer1, A Fredriksson, B Johansson.   

Abstract

The present review examines the putative benefits for individuals afflicted with Parkinsonism, whether in the clinical setting or in the animal laboratory, accruing from different exercise regimes. The tendency for patients with Parkinson's disease (PD) to express either normal or reduced exercise capacity appears regulated by factors such as fatigue, quality-of-life and disorder severity. The associations between physical exercise and risk for PD, the effects of exercise on idiopathic Parkinsonism and quality-of-life, the effects of exercise on animal laboratory models of Parkinsonism and dopamine (DA) loss following neurotoxic insults, and the effects of exercise on the DA precursor, L-Dopa, efficacy are examined. It would appear to be case that in view of the particular responsiveness of the dopaminergic neurons to exercise, the principle of 'use it or lose' may be of special applicability among PD patients.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21108623     DOI: 10.1111/j.1600-0404.2010.01360.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  19 in total

1.  Delayed exercise-induced functional and neurochemical partial restoration following MPTP.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2011-08-10       Impact factor: 3.911

Review 2.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

3.  The yeast product Milmed enhances the effect of physical exercise on motor performance and dopamine neurochemistry recovery in MPTP-lesioned mice.

Authors:  Trevor Archer; Anders Fredriksson
Journal:  Neurotox Res       Date:  2013-07-27       Impact factor: 3.911

Review 4.  Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-07-15       Impact factor: 3.911

5.  Variability in cadence during forced cycling predicts motor improvement in individuals with Parkinson's disease.

Authors:  Angela L Ridgel; Hassan Mohammadi Abdar; Jay L Alberts; Fred M Discenzo; Kenneth A Loparo
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2012-10-24       Impact factor: 3.802

6.  A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson's disease.

Authors:  Jeff A Beeler; Michael J Frank; John McDaid; Erin Alexander; Susie Turkson; Maria Sol Bernardez Sarria; Maria Sol Bernandez; Daniel S McGehee; Xiaoxi Zhuang
Journal:  Cell Rep       Date:  2012-12-13       Impact factor: 9.423

7.  Novel, high-intensity exercise prescription improves muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's disease.

Authors:  Neil A Kelly; Matthew P Ford; David G Standaert; Ray L Watts; C Scott Bickel; Douglas R Moellering; S Craig Tuggle; Jeri Y Williams; Laura Lieb; Samuel T Windham; Marcas M Bamman
Journal:  J Appl Physiol (1985)       Date:  2014-01-09

Review 8.  Influence of physical exercise on traumatic brain injury deficits: scaffolding effect.

Authors:  Trevor Archer
Journal:  Neurotox Res       Date:  2011-12-20       Impact factor: 3.911

9.  Physical exercise alleviates ADHD symptoms: regional deficits and development trajectory.

Authors:  Trevor Archer; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2011-08-18       Impact factor: 3.911

10.  Running wheel activity restores MPTP-induced functional deficits.

Authors:  Anders Fredriksson; Ingels Maria Stigsdotter; Anders Hurtig; Béatrice Ewalds-Kvist; Trevor Archer
Journal:  J Neural Transm (Vienna)       Date:  2010-09-18       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.